Home
Post
Share
@CovidAnalysis
Meta AnalysisMeta
Montelukast has a boxed warning for neuropsychiatric side effects fda.gov.
Submit updates/corrections .
Summary.
Dec 21 |
Montelukast reduces COVID-19 risk: real-time meta analysis of 9 studies | |
| Significantly lower risk is seen for hospitalization and cases. 4 studies from 4 independent teams in 4 countries show significant benefit. Meta analysis using the most serious outcome reported shows 39% [14‑56%] lower risk. Re.. | ||
Nov 21 |
et al., Discover Molecules, doi:10.1007/s44345-024-00005-5 | Exploring potential therapeutic candidates against COVID-19: a molecular docking study |
| In Silico study showing potential inhibition of SARS-CoV-2 proteins by various compounds including dactinomycin, itraconazole, ivermectin, vitamin D, quercetin, curcumin, montelukast, bromhexine, hesperidin, EGCG and raloxifene. Authors p.. | ||
Aug 5 |
et al., Genel Tıp Dergisi, doi:10.54005/geneltip.1352153 | The Effect of Montelukast Treatment on Elderly Patients Diagnosed with COVID-19 |
| 14% lower mortality (p=1), 90% higher ICU admission (p=0.46), and 3% shorter hospitalization (p=0.81). Retrospective 75 hospitalized COVID-19 patients over 60 in Turkey showing no significant differences with montelukast treatment. | ||
May 18 |
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2024.39332 (date from preprint) | Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo |
| 1% fewer combined hospitalization/ER visits (p=1), 48% higher progression (p=0.29), and 2% improved recovery (p=0.72). RCT 1,250 outpatients with mild to moderate COVID-19 showing no significant difference in time to sustained recovery with montelukast treatment. There were no deaths and only 2 hospitalizations in each group. Notably, results were better .. | ||
Sep 23 2023 |
et al., Qatar Medical Journal, doi:10.5339/qmj.2023.15 | Characteristics and outcomes of adult patients with asthma presenting with COVID-19: A comparative cohort study |
| 13% lower hospitalization (p=0.61). Retrospective 616 COVID-19 patients with asthma in Qatar showing no significant difference in hospitalization risk with montelukast use. | ||
Aug 31 2023 |
et al., NCT04695704 | Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: E-SPERANZA COVID-19 PROJECT |
| Estimated 284 patient montelukast late treatment RCT with results not reported over 1 year after estimated completion. | ||
Jul 5 2023 |
et al., Pharmaceutics, doi:10.3390/pharmaceutics15071891 | Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant |
| In Silico and In Vitro study showing that montelukast and telmisartan inhibit SARS-CoV-2 wild-type and the omicron variant. In Silico analysis found montelukast and telmisartan bind to the SARS-CoV-2 spike protein receptor binding domain .. | ||
Mar 30 2023 |
et al., Biomedical Research Bulletin, doi:10.34172/biomedrb.2023.06 | Effect of Montelukast on Treatment of Coronavirus Pneumonia (COVID-19): A Systematic Review |
| Systematic review of 8 studies showing improved symptoms, clinical deterioration, hospitalization length, and mortality with montelukast treatment for COVID-19 patients. | ||
Mar 19 2023 |
, M., Expert Opinion on Pharmacotherapy, doi:10.1080/14656566.2023.2192866 | Montelukast as a potential treatment for COVID-19 |
| Review of montelukast as a potential treatment for COVID-19. | ||
Sep 15 2022 |
et al., The Egyptian Journal of Bronchology, doi:10.1186/s43168-022-00154-6 | Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study |
| 50% improved recovery (p<0.0001). RCT 68 post-COVID-19 outpatients showing improvement in cough severity measures with montelukast treatment. The montelukast group had a greater reduction in number of cough paroxysms per day, cough severity visual analog scale, cough seve.. | ||
Jul 31 2022 |
et al., The Clinical Respiratory Journal, doi:10.1111/crj.13529 | The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID‐19‐ related cough: A randomized, controlled clinical trial |
| 20% shorter hospitalization (p=0.01) and 25% improved recovery (p=0.0006). RCT 180 hospitalized COVID-19 patients showing improved cough frequency and severity with gabapentin and gabapentin/montelukast compared to dextromethorphan, with the combination being more efficacious. The gabapentin/montelukast group ha.. | ||
Jun 1 2022 |
et al., NCT04718285 | A National, Multi-Center, Open-Label, Three-Arm, Phase II Study to Investigate the Effect of Montelukast Between Emergency Room Visits and Hospitalizations in COVID-19 Pneumonia in Comparison With Standard Treatment |
| Estimated 380 patient montelukast early treatment RCT with results not reported over 2 years after estimated completion. | ||
Feb 28 2022 |
et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.108412 | Levocetirizine and montelukast in the COVID-19 treatment paradigm |
| Retrospective 53 patients reporting a potential benefit with levocetirizine and montelukast treatment for COVID-19. 51 of 53 patients were considered clinically cured on the combination therapy, with symptom resolution typically within 7 .. | ||
Feb 8 2022 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.784214 | Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients |
| In Vitro study showing that montelukast inhibits platelet activation induced by plasma from COVID-19 patients. Authors demonstrate that montelukast prevents the surface expression of tissue factor (TF) and P-selectin on platelets, reduces.. | ||
Jan 4 2022 |
et al., Journal of Medical Virology, doi:10.1002/jmv.27552 | Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID‐19 |
| 92% lower mortality (p=0.01), 81% lower progression (p=0.007), and 15% shorter hospitalization (p=0.04). RCT 180 hospitalized COVID-19 patients in Turkey showing faster reduction in inflammatory markers, improved pulmonary function, and lower rates of macrophage activation syndrome, respiratory failure and mortality with montelukast treatmen.. | ||
Nov 22 2021 |
et al., International Journal of Basic & Clinical Pharmacology, doi:10.18203/2319-2003.ijbcp20214502 | Efficacy of montelukast in the management of COVID-19: double blind randomized placebo controlled trial |
| 67% lower ICU admission (p=0.62), 25% higher progression (p=0.79), and no change in hospital discharge (p=1). RCT 90 mild to moderate COVID-19 patients showing no significant differences with montelukast treatment. | ||
Mar 4 2021 |
et al., Journal of Asthma, doi:10.1080/02770903.2021.1881967 | Montelukast in hospitalized patients diagnosed with COVID-19 |
| 64% lower progression (p=0.09) and 12% shorter hospitalization (p=0.33). Retrospective 92 hospitalized patients showing lower clinical deterioration with montelukast treatment, without statistical significance in multivariable analysis. The treatment group was older. | ||
Feb 10 2021 |
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.02.014 | Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico |
| 78% lower mortality (p=0.001), 52% lower ventilation (p=0.15), 67% lower hospitalization (p=0.001), and 59% improved recovery (p=0.001). Prospective trial of 768 COVID-19 outpatients in Mexico, 481 treated with ivermectin, AZ, montelukast, and aspirin, and 287 control patients with various treatments, showing significantly lower mortality and hospitalization, and significa.. | ||
Sep 17 2020 |
et al., Journal of Asthma, doi:10.1080/02770903.2020.1786112 | Montelukast’s ability to fight COVID-19 infection |
| 91% lower hospitalization (p=0.02) and 82% fewer cases (p=0.004). Retrospective 445 elderly patients with severe asthma showing reduced risk of COVID-19 infection with montelukast treatment. | ||
Sep 4 2020 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2020.01344 | Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence |
| Review of evidence that montelukast may improve COVID-19 prognosis. Authors note ten experimentally supported properties of montelukast that could be beneficial, including antiviral effects, prevention of SARS-CoV-2-induced endotheliitis .. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.